1Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase Ⅲ study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma[J]. J Clin Oncol, 2000, 18(1):158-166.
2Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase Ⅲ study[J]. J Clin Oncol, 2004, 22(6): 1118-1125.
3Garbe C, Radny P, Linse R, et al. Adjuvant low-dose in- terferon α-2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase Ⅲ DeCOG trial in melanoma patients with regional lymph node metastasis[J]. Ann Oncol, 2008, 19(6): 1195-1201.
4Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5mm tumor thickness: results of a randomized phase Ⅲ DeCOG trial[J]. J Clin Oncol, 2010, 28(5):841-846.
5Hodi FS, O'Day SJ, McDermott DF, et al. Improved sur- vival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8):711-723.
6Wei Wang1,2, Yuan-Fang Li1,2, Xiao-Wei Sun1,2, Gong Chen1,3, You-Qing Zhan1,2, Chun-Yu Huang1,2, De-Sen Wan1,3, Zhi-Zhong Pan1,3, Zhi-Wei Zhou1,2 1 State Key Labortary of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China,2 Department of Gasrtic and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China,3 Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China.Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-Ⅱ colon cancer patients[J].Chinese Journal of Cancer,2010,29(8):761-767. 被引量：7
7Rao RD, Hohan SG, Ingle JN, et al. Combination of pacli- taxel and carboplatin as second-line therapy for patients with metastatic melanoma [J]. Cancer, 2006, 106 (2):375- 382.
8Kirkwood JM, Strawderman MH, Ernstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684[J]. J Clin Oncol, 1996, 14(1): 7-17.
9Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase Ⅲ study of 1 month versus 1 year of adjuvant high- dose interferon alfa-2b in patients with resected high-risk melanoma[J]. J Clin Oncol, 2009, 27(6):939-944.
10Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observa- tion alone in resected stage Ⅲ melanoma: final results of EORTC 18991, a randomized phase Ⅲ trial [J]. Lancet, 2008, 372(9633): 117-126.
8Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma European consensus based interdisciplinary guideline[J]. Eur J Cancer, 2010,46(2) :270-283.
9Lin Y, Han C D, Mei S, et al. Akt/ protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt [J]. Cancer Res, 2004,64(13) :4394.
10Alex T, Merav Y L. Akt Signaling and cancer surviving but not moving on[J]. Cancer Res, 2006,66(9) :3963-3966.
